| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Here's a roundup of top developments in the biotech space over the last 24 hours.
(Biotech Stocks Hitting 52-week highs on Feb. 11)
(Biotech Stocks Hitting 52-week lows on Feb. 11)
Johnson & Johnson (NYSE:JNJ) said its Janssen unit will further expedite the development of its investigational COVID-19 vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority at the U.S. Department of Health & Human Sciences.
Apart from Janssen's efforts to develop a vaccine candidate, J&J said the unit will also work closely with global partners to screen its library of antiviral molecules to accelerate the discovery of potential COVID-19 treatments.
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced publication of final results from a two-year, open-label study of Gocovri extended release capsules in Parkinson's disease, showing a sustained improvement in levodopa-induced dyskinesia, or LID.
"This study further demonstrates that the only FDA-approved medicine for dyskinesia may help people with PD who are struggling to manage these levodopa-related motor complications over this long period of time," the company said.
The results were published online in the Journal of Parkinson's Disease.
The stock gained 4.28% to $5.85 in after-hours trading.
Eli Lilly And Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced baricitinib, an oral selective JAK inhibitor, met the primary endpoint in a Phase 3 study dubbed BREEZE-AD5 that evaluated the investigational therapy for the treatment of adults with moderate-to-severe atopic dermatitis.
The primary endpoint was the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index, or EASI, at Week 16.
FibroGen Inc (NASDAQ:FGEN) said the FDA has accepted its NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis dependent and dialysis-dependent patients. The FDA has set a PDUFA date of Dec. 20, 2020.
The stock added 4.41% to $46.60 in after-hours trading.
EXACT Sciences Corporation (NASDAQ:EXAS) reported fourth-quarter revenues of $295.58 million, up from $142.98 million a year ago. Screening revenues climbed 60% to $229.4 million and test volume was up 63% to 477,000. The company reversed to a profit of 54 cents per share from a loss of 44 cents per share, while analysts estimated a loss of 35 cents per share.
For 2020, the company guided to revenues of $1.61 billion to $1.645 billion, ahead of the $1.59 billion consensus estimate.
The stock slipped 0.83% to $94.
PDS Biotechnology said it has priced its underwritten public offering of 9.23 million shares at $1.30 per share. The company expects to raise gross proceeds of $12 million, with the offering expected to close Friday.
The stock plunged 24.16% to $1.35 in after-hours trading.
Zosano Pharma Corp (NASDAQ:ZSAN) announced the commencement of an underwritten public offering of units comprising shares of its common stock and warrants to purchase its common stock. All the units are to be sold by the company.
The stock slipped 21.78% to 75 cents in after-hours trading.
At the 2020 WORLDSymposium, Regenxbio Inc (NASDAQ:RGNX) will make poster presentation of interim data from the Phase 1/2 trial of its investigational gene therapy RGX-121 for the treatment of Mucopolysaccharidosis Type II. The presentation is scheduled at the WORLDSymposium for Wednesday between 4:30 and 6:30 p.m. ET.
Avrobio Inc (NASDAQ:AVRO) is due to present at the WORLDSymposium updated Phase 2 data for AVR-RD-01 in Fabry disease.
Kala Pharmaceuticals Inc (NASDAQ:KALA) (before the market open)
Veru Inc (NASDAQ:VERU) (before the market open)
Posted In: ABBV ADMS ADXN AGN AGRX AKBA ALNY ASND ATRC AVRO BBI CCXI CUE CYTK DCPH DXCM ELGX ENZ EOLS ESPR
